Literature DB >> 9892185

Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

D B Chappell1, T Z Zaks, S A Rosenberg, N P Restifo.   

Abstract

A recent report described the expression of Fas ligand (FasL) by melanoma cells as an important mechanism involved in the immune evasion by tumors [M. Hahne et al., Science (Washington DC), 274: 1363-1366, 1996]. To investigate the expression of FasL by melanomas, we screened a panel of early-passage cell lines by functional assay and reverse transcriptase-PCR. Using conditions designed to replicate those in the original report, we did not find functional FasL on any of the 19 human melanoma lines established at the National Cancer Institute. Furthermore, we additionally evaluated our melanoma lines using reverse transcriptase-PCR and found that 0 of the 26 human melanoma cell lines expressed FasL mRNA. FasL mRNA was abundantly expressed by anti-melanoma T-cell lines after activation. These data do not support a role for FasL expression in the escape of melanoma cells from immune destruction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892185      PMCID: PMC2239006     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes.

Authors:  R G Fenton; D L Longo
Journal:  J Natl Cancer Inst       Date:  1997-02-19       Impact factor: 13.506

2.  Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases.

Authors:  A Sarin; M S Williams; M A Alexander-Miller; J A Berzofsky; C M Zacharchuk; P A Henkart
Journal:  Immunity       Date:  1997-02       Impact factor: 31.745

3.  Antitumor effect of locally produced CD95 ligand.

Authors:  K Seino; N Kayagaki; K Okumura; H Yagita
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

Review 4.  The role of the Caspase family of cysteine proteases in apoptosis.

Authors:  D K Miller
Journal:  Semin Immunol       Date:  1997-02       Impact factor: 11.130

5.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

Authors:  J Allison; H M Georgiou; A Strasser; D L Vaux
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.

Authors:  K Shiraki; N Tsuji; T Shioda; K J Isselbacher; H Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

7.  Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.

Authors:  S Ehl; U Hoffmann-Rohrer; S Nagata; H Hengartner; R Zinkernagel
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

8.  Sequential development of structural and functional alterations in T cells from tumor-bearing mice.

Authors:  M R Correa; A C Ochoa; P Ghosh; H Mizoguchi; L Harvey; D L Longo
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

9.  Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.

Authors:  M Hahne; D Rimoldi; M Schröter; P Romero; M Schreier; L E French; P Schneider; T Bornand; A Fontana; D Lienard; J Cerottini; J Tschopp
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

10.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  30 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 3.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

4.  Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.

Authors:  Xiaomu Wei; Todd D Prickett; Cristina G Viloria; Alfredo Molinolo; Jimmy C Lin; Isabel Cardenas-Navia; Pedro Cruz; Steven A Rosenberg; Michael A Davies; Jeffrey E Gershenwald; Carlos López-Otín; Yardena Samuels
Journal:  Mol Cancer Res       Date:  2010-10-13       Impact factor: 5.852

Review 5.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

6.  Cancer therapy using a self-replicating RNA vaccine.

Authors:  H Ying; T Z Zaks; R F Wang; K R Irvine; U S Kammula; F M Marincola; W W Leitner; N P Restifo
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

7.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.

Authors:  T Z Zaks; D B Chappell; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

8.  Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; Yong F Li; Xiaoqiang Kang; Rejean Lapointe; Patrick Hwu; Steven A Rosenberg; Nicholas P Restifo
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

9.  Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

Authors:  Hector Guillen-Ahlers; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

10.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

Authors:  Todd D Prickett; Neena S Agrawal; Xiaomu Wei; Kristin E Yates; Jimmy C Lin; John R Wunderlich; Julia C Cronin; Pedro Cruz; Steven A Rosenberg; Yardena Samuels
Journal:  Nat Genet       Date:  2009-08-30       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.